Showcase Track S1 - January 25 3.30 P.M.-4.00 P.M.,Showcase Track S1 - January 26 9.15 A.M.-9.30 A.M.,Showcase Track S1 - January 27 1.45 P.M.-2.00 P.M.
Confirmed Presenting Companies:
Speaker Profile
Ph.D., FACMG, Chief Medical Officer, LetsGetChecked
Biography
Dr. Santani holds over 20 years of experience in the diagnostics and healthcare industry sectors. Prior to Veritas, a LetsGetChecked company, she was most recently the Director of Clinical Laboratories and Strategic Initiatives at the Center for Applied Genomics at The Children’s Hospital of Philadelphia and an Associate Professor of Pathology at the University of Pennsylvania. She formerly held roles within CHOP including within the Division of Genomic Diagnostics and within the Molecular Genetics Laboratory. At CHOP, Dr. Santanis work focused on creating a comprehensive diagnostics program by developing innovative technologies for diagnostics, forming public-private partnerships and discovery of novel genes associated with complex genetic disorders. At Veritas, she is responsible for the strategy, direction, and execution of clinical development plans and medical affairs. Under her leadership, the multi-disciplinary programs at Veritas includes the clinical laboratory operations, research, and clinical development including whole genome sequencing programs, pharmacogenomics and high throughput Covid testing.
Talk
Pharmacogenomics (PGx) Showcase:
LetsGetChecked
LetsGetChecked is a leading healthcare solutions company that provides consumers, employees, and health plan members the tools to manage their health from home, with direct access to health insights, at-home diagnostics, genomics, virtual care, and pharmacy for a wide range of health conditions.
Introducing myPGx by LetsGetChecked
Learn about LetsGetChecked's recent launch, myPGx, a comprehensive pharmacogenomics test powering precision medicine from home.
Speaker Profile
M.D., Ph.D., MPH, Postdoctoral Scholar, UCSF
Biography
Dr. Zastrozhin made significant and widely recognized contributions to the study of pharmacoepidemiology and the development of personalized medicine at the international level, including the study of the complex mutual influence of omics biomarkers (pharmacogenomic, pharmacometabolomic, pharmacotranscriptomic), as well as their influence on individual drug responses. With more than a decade of academic, clinical, and research experience in these fields, he has exceptional publications and citations record (>80 articles, many first-co-first authored, ~8,000 citations, >80% independent). His work has had a substantial and enduring impact on personalized medicine.
Talk
Pharmacogenomics (PGx) Showcase:
UCSF
The University of California, San Francisco is a public land-grant research university in San Francisco, California. It is part of the University of California system and is dedicated entirely to health science and life science.
Omics technologies to improve the quality of therapy
The relationship of microRNAs, activity of isoenzymes of biotransformation, pharmacogenetics and pharmacokinetics, efficacy and safety of drugs.
Speaker Profile
Ph.D., Chief Science Officer, Precision Genetics
Biography
Jeremy has extensive management experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, start-up, and analytical validation of laboratory-developed tests (LDTs). Jeremy was a key member of the Agencourt Personal Genomics team. Jeremy led the development and validation of all of Selah’s molecular assays and led the commercialization and application efforts for next generation sequencing at Life Technologies. While at Agencourt Personal Genomics, Jeremy was a co-developer of the SOLiD next-generation sequencing technology, where he co-authored several patents related to next-generation sequencing. Before entering the industry, Jeremy completed his postdoctoral work at the Dept. of Genetics & Complex Diseases at the Harvard School of Public Health. Jeremy earned his master’s degree in Toxicology from the University of Minnesota and his doctorate from Harvard University.
Talk
Leverage the Utility of Pharmacogenomics for Perioperative Treatments
Postoperative pain control remains a challenge for providers without a routine way to select personalized medication. Postop outcomes can show great improvement with pharmacogenetics analysis of multiple gene variants. Learn more about the Prospective Outcomes and Molecular Implementation Support Registry (PROMISRx) Study to better explain interpatient variability in response to perioperative treatment.
Pharmacogenomics (PGx) Showcase:
Precision Genetics
